A new blood biomarker ratio using neutrophil CD64 and monocyte CD169 demonstrated 100% sensitivity and 96.6% specificity for distinguishing bacterial from viral infections in febrile infants, according to study data presented at EEMC 2024.
CMS has released preliminary 2027 CLFS rates, with data showing weighted median payment cuts for over 1,100 test codes; annual reductions are capped at 15% from 2027 to 2029 under current policy.
An FDA advisory panel voted 7-2 that the benefits of GRAIL’s Galleri multi-cancer early detection blood test outweigh its risks for adults 50 and older, supporting its premarket approval application.
OGT has launched automation-enabled SureSeq NGS workflows compatible with the Hamilton NGS STAR Line, aiming to reduce manual steps and increase throughput for clinical research labs managing higher sample volumes.
Tampa General Hospital is the first in the Southeast to implement the MeMed BV host-response test in its emergency workflow, reporting a 33% reduction in cefepime use and 13% fewer hospitalizations, according to hospital-led research.
